logo
 

logo
  • Home
  • Burden of Disease  
    • Heterogeneity of SLE
    • Risk of organ damage
    • Disease Outcomes
  • Pathophysiology of Disease 
    • Immune Dysregulation
    • Role of Cytokines
    • Significance of IFN-1
  • Expert On-Demand
  • Learn More 
    • View AstraZeneca’s Commitment to SLE
    • Connect With a Medical Science Liaison
Home

Heterogeneity of SLE Risk of organ damage Disease Outcomes

Immune Dysregulation Role of Cytokines Significance of IFN-1
Expert On-Demand

View AstraZeneca’s Commitment to SLE Connect With a Medical Science Liaison

Heterogeneity of SLE

Risk of organ damage

Disease Outcomes

Immune Dysregulation

Role of Cytokines

Significance of IFN-1

View AstraZeneca’s Commitment to SLE

Connect With a Medical Science Liaison

Expert On-Demand

Welcome to Unlocking-lupus Egypt

This website is intended to help healthcare professionals practicing in Egypt find and access scientifically balanced, evidence-based, and peer-led information and professional resources in support of the early diagnosis and timely referral of patients with lupus. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

Self Certification Buttons
Go to Patient website Self Certification Buttons
 

Unlocking lupus

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune rheumatic disease in which disease flares are interspersed with episodes of remission.1
SLE is the result of multiple defects in both the innate and adaptive immune system with altered immune tolerance and hyperactivation of T- and B-cells.1
Innate immune cells are recruited and produce pathogenic cytokines, such as IFN-α, tumor necrosis factor and IL-1 with abnormal IFN-I regulation. 1
By understanding the pathogenesis, molecular and cellular biology of SLE, we can now move towards the development of targeted therapies for SLE.1
IFN-1, type 1 interferon; IL, interleukin; SLE, systemic lupus erythematosus.

DividerDivider
Learn about the heterogeneity of SLE

References:

1. Shaikh, M.F., Jordan, N. and D’Cruz, D.P. (2017) ‘Systemic lupus erythematosus’, Clinical Medicine, 17(1), pp. 78–83. doi:10.7861/clinmedicine.17-1-78.

  • Privacy Notice
  • Cookie Policy
  • Legal Notice and Terms of Use
  • Contact Us

The information on this website is provided by AstraZeneca for educational purposes only and is intended for non-UK and non-US Healthcare Professionals only. It should not be used for diagnosing or treating a health problem or disease. This information is intended for Healthcare Professionals only.

EDA Notification No : WF0022OA6344/052026

Invalidation Date : 25/08/2026

Promomat Code : EG-9767

Promomat Expiration Date : 5/21/2027